Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: A two-year outcome study

Annals of Neurology

Volumn 57, Issue 2, 2005, Pages 298-302

  Patel, Nikunj K ^a   Bunnage, Martin ^a   Plaha, Puneet ^a   Svendsen, Clive N ^b   Heywood, Peter ^a   Gill, Steven S ^a  

^a FRENCHAY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR;

ARTICLE; CLINICAL ARTICLE; COGNITION; DAILY LIFE ACTIVITY; HEADACHE; HUMAN; HYPERSALIVATION; MOTOR ACTIVITY; MOUTH ULCER; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SIDE EFFECT; SMELLING DISORDER; TASTE DISORDER; VIVID DREAM;

ACTIVITIES OF DAILY LIVING; CATHETERS, INDWELLING; COGNITION; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; INJECTIONS, INTRAVENTRICULAR; MOTOR ACTIVITY; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; PARKINSON DISEASE; PUTAMEN; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 13144282676     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20374     Document Type: Article

References (16)

1. Lin LF, Doherty DH, Lile JD, et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993;260:1130-1132.
2. Beck KD, Valverde J, Alexi T, et al. Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 1995;373:339-341.
3. Tomac A, Lindqvist E, Lin LF, et al. Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 1995;373:335-339.
4. Bjorklund A, Rosenblad C, Winkler C, Kirik D. Studies on neuroproteccive and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol Dis 1997;4: 186-200.
5. Gash DM, Zhang Z, Ovadia A, et al. Functional recovery in parkinsonian monkeys treated with GDNF. Nature 1996;380: 252-255.
6. Nutt JG, Burchiel KJ, Cornella CL, et al. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD, Neurology 2003;60:69-73.
7. Kordower JH, Palfi S, Chen EY, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 1999;46:419-424.
8. Gill SS, Patel NK, Hotton GR, et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003;9:589-595.
9. Langston JW, Widner H, Goetz CG, et al. Core Assessment Program for Intracerebral Transplantations (CAPIT). Mov Disord 1992;7:2-13.
10. McCarter RJ, Walton NH, Rowan AF, et al. Cognitive functioning after subthalamic nucleotomy for refractory Parkinson's disease. J Neurol Neurosurg Psychiatry 2000;69;60-66.
11. Lord FM, Novick, M.R. Statistical theories of mental test scores. Reading, MA: Addison-Wesley, 1968.
12. Atkinson L. Three standard errors of measurement and the Wechsler Memory Scale -Revised. Psychol Assess 1991;3: 136-138.
13. Jenkinson C, Fitzpatrick R, Peto V. The Parkinson's disease questionnaire: User manual for the PDQ-39, PDQ-8 and PDQ summary index. Oxford; Health Services Research Unit, Department of Public Health, University of Oxford, 1998.
14. Riazi A, Hobart JC, Lamping DL, et al. Using the SF-36 measure to compare the health impact of multiple sclerosis and Parkinson's disease with normal population health profiles. J Neurol Neurosurg Psychiatry 2003;74:710-714.
15. Hotton GR, Patel NK, Gill SS, et al. The long term effect of glial derived neurotrophic factor infusions and 18F-dopa uptake in Parkinson's disease. Neurology 2004;62:S38.001; A345.
16. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease, N Engl J Med 2001;344:710-719.